In 12-week, multicenter, randomized, double-blind studies in adult patients with persistent asthma, treatment with montelukast resulted in significant improvements in respiratory function, asthma symptoms, as-needed β2-agonist use, peripheral eosinophil counts, and health-related quality of life. Furthermore, Pizzichini et al demonstrated that 4 weeks of treatment with mon-telukast resulted in decreases in both sputum and peripheral blood eosinophils, suggesting that this drug may exert anti-inflammatory actions in patients with asthma. canadian health & care mall
In this study, we investigated the effects of mon-telukast on airway inflammation and airway hyperresponsiveness in patients with mild-to-moderate asthma in a randomized, double-blind, placebo-controlled, two-period crossover study. Furthermore, the correlation between the decrease in sputum eosinophils and the increase in peak expiratory flow (PEF) was also evaluated.
Twenty-nine adults with mild-to-moderate bronchial asthma, who were capable of producing induced sputum before the study and had > 10% sputum eosinophils, were enrolled from among outpatients of the First Department of Internal Medicine, Showa University; the Department of Respirology, Kihara Hospital; and the Department of Allergy and Respiratory Medicine, Doai Memorial Hospital, Tokyo, Japan. The severity of bronchial asthma in patients participating in this study was considered mild to moderate based on the Japanese Guideline for the Treatment of Asthma. All of the patients had demonstrated an improvement of > 15% in FEV1 after inhalation of 200 |j,g of salbutamol sulfate within 1 year before entering the study. All of the patients were nonsmokers for at least 6 months before starting this study. None of the patients received any type of steroids within 4 weeks before enrollment or anti-allergy agents, including antihistamines, within 2 weeks before enrollment.